ReceptivaDxTM is a new and improved non-surgical test for endometrial receptivity that provides enhanced screening for ALL stages of endometriosis and other conditions that interfere with implantation. The test specifically identifies BCL6, a gene biomarker that is present in the setting of inflammation and/or endometriosis. This is the first non-surgical test for endometriosis with high sensitivity and specificity (96%), especially useful in women with unexplained infertility or IVF failures. ReceptivaDx (BCL6 Test) predicts chances for a successful transfer and successful pregnancy.
The test can also detect recurring endometriosis in patients previously diagnosed and treated for the condition. Endometriosis is considered to be the leading cause of unexplained infertility, IVF transfer failure and recurrent pregnancy loss.
NCFMC is proud to offer the ReceptivaDX to our eligible patients. For more information, please download the patient information brochure.
If you would like to make an appointment with one our Northern California Fertility Medical Center physicians to discuss whether you may be a candidate for ReceptivaDx, please contact us!